Q-omics provides the consensus-scored VKORC1 profile across patient tissues and cancer cell-line models. VKORC1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, VKORC1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, VKORC1 protein abundance shows 21,745 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UCS, KIRC, and BRCA as cancer lineages where VKORC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VKORC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VKORC1 survival associations across molecular data types. VKORC1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VKORC1 RNA expression–survival associations across cancer types. High VKORC1 expression shows unfavorable associations in UCS, BLCA, BRCA, LGG, KIRC and HNSC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for VKORC1 RNA expression.
This table summarizes VKORC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for VKORC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VKORC1 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, KIRP, LUAD and COAD. The KIRC box plot shows higher VKORC1 RNA expression in tumor versus normal tissue (log2 FC = +1.478, t-test p < 0.001).
This table shows molecular features associated with VKORC1 in patient tissues and cancer cell lines. In patient samples, VKORC1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, VKORC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
